Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Syndax Pharmaceuticals, Inc. - Common Stock (NQ:SNDX)

24.70 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 26, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	0
Open	24.70
Bid (Size)	9.940 (100)
Ask (Size)	25.50 (100)
Prev. Close	24.70
Today's Range	24.70 - 24.70
52wk Range	8.580 - 25.59
Shares Outstanding	69,484,053
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Syndax Pharmaceuticals Inc (NASDAQ:SNDX) Emerges as a High-Growth Momentum Pick Using Minervini's Trend Template ↗

March 26, 2026

Via Chartmill

This Biotech Stock Winner Is Up 72%, but a $4 Million Trim Signals a Slight Reset ↗

March 21, 2026

This clinical-stage biotech develops oncology therapies targeting unmet needs in cancer and immune-mediated conditions.

Via The Motley Fool

Performance

YTD	+16.0%	+16.0%
1 Month	+20.3%	+20.3%
3 Month	+16.0%	+16.0%
6 Month	+64.3%	+64.3%
1 Year	+88.1%	+88.1%

More News

High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding ↗

March 21, 2026

Via The Motley Fool

This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know ↗

March 21, 2026

Via The Motley Fool

Syndax Pharmaceuticals Inc (NASDAQ:SNDX) Reports Mixed Q4 2025 Results with Revenue Beat and Wider-Than-Expected Loss ↗

February 26, 2026

Via Chartmill

This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know ↗

March 21, 2026

Via The Motley Fool

Biotech Stock Up 72% Sees $8 Million Sale, but Here's Why One Fund Still Seems Bullish ↗

March 21, 2026

Via The Motley Fool

Cancer Drug Maker With $172 Million Revenue and Multiple Approved Therapies Draws $6.5 Million Investment ↗

March 13, 2026

Via The Motley Fool

Biotech Stock Up 365% as This $8 Million Investment Targets a Drug With 3 NDA Filings Planned ↗

March 13, 2026

Via The Motley Fool

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

March 04, 2026

From Syndax Pharmaceuticals, Inc.

Via GlobeNewswire

Syndax (SNDX) Q4 2025 Earnings Call Transcript ↗

February 27, 2026

Via The Motley Fool

Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

February 26, 2026

From Syndax Pharmaceuticals, Inc.

Via GlobeNewswire

Syndax Announces Participation in March Investor Conferences

February 23, 2026

From Syndax Pharmaceuticals, Inc.

Via GlobeNewswire

Syndax to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on February 26, 2026

February 19, 2026

From Syndax Pharmaceuticals, Inc.

Via GlobeNewswire

Syndax Announces Participation at the 2026 Guggenheim Emerging Outlook: Biotech Summit

February 05, 2026

From Syndax Pharmaceuticals, Inc.

Via GlobeNewswire

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

February 04, 2026

From Syndax Pharmaceuticals, Inc.

Via GlobeNewswire

Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference

January 12, 2026

From Syndax Pharmaceuticals, Inc.

Via GlobeNewswire

Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj® (revumenib) Outside the U.S.

January 07, 2026

From Syndax Pharmaceuticals, Inc.

Via GlobeNewswire

Syndax Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference

January 05, 2026

From Syndax Pharmaceuticals, Inc.

Via GlobeNewswire

The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally

December 22, 2025

Via MarketMinute

Revuforj® (revumenib) Named Best New Drug at the Scrip Awards 2025

December 12, 2025

From Syndax Pharmaceuticals, Inc.

Via GlobeNewswire

Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum

December 08, 2025

From Syndax Pharmaceuticals, Inc.

Via GlobeNewswire

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

December 03, 2025

From Syndax Pharmaceuticals, Inc.

Via GlobeNewswire

Syndax Announces Participation at the 8th Annual Evercore Healthcare Conference

December 01, 2025

From Syndax Pharmaceuticals, Inc.

Via GlobeNewswire

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

November 05, 2025

From Syndax Pharmaceuticals, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Syndax Pharmaceuticals, Inc. - Common Stock publicly traded?

Yes, Syndax Pharmaceuticals, Inc. - Common Stock is publicly traded.

What exchange does Syndax Pharmaceuticals, Inc. - Common Stock trade on?

Syndax Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Syndax Pharmaceuticals, Inc. - Common Stock?

The ticker symbol for Syndax Pharmaceuticals, Inc. - Common Stock is SNDX on the Nasdaq Stock Market

What is the current price of Syndax Pharmaceuticals, Inc. - Common Stock?

The current price of Syndax Pharmaceuticals, Inc. - Common Stock is 24.70

When was Syndax Pharmaceuticals, Inc. - Common Stock last traded?

The last trade of Syndax Pharmaceuticals, Inc. - Common Stock was at 03/26/26 04:00 PM ET

What is the market capitalization of Syndax Pharmaceuticals, Inc. - Common Stock?

The market capitalization of Syndax Pharmaceuticals, Inc. - Common Stock is 1.72B

How many shares of Syndax Pharmaceuticals, Inc. - Common Stock are outstanding?

Syndax Pharmaceuticals, Inc. - Common Stock has 2B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.